For more information, please visit the EACR 2025 website. Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune ...

Purple Biotech (PPBT) has released an update. Purple Biotech Ltd., a clinical-stage bio-pharmaceutical company, is set to present its groundbreaking CAPTN-3 platform at the EORTC-NCI-AACR Symposium.

Purple Biotech shares are trading lower by 27.7% during Tuesday's session. The company announced a $2.8 million offering. Memorial Day Special: Access your full investing command center with ...

26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal ...

Shares of Purple Biotech ($PPBT) surged more than 45% on Monday morning, reaching their highest levels since early October. The Israel-based biopharma reported ...

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology ...

Purple Biotech is adding Immunorizon’s tri-specific antibodies to its paint palette in an acquisition that could reach $100 million. The M&A deal, announced Thursday morning, will see privately ...

Purple Biotech hopes its lead asset against metastatic pancreatic cancer will one day show its true colors as a potential first-in-class drug in a larger study—but, for now, it has preliminary ...